journal article·2024-09-25

Engineered Platelet for In Situ Natural Killer Cell Activation to Inhibit Tumor Recurrence

Yueyang Deng, Caixia Tan, Shuguang Huang, Zhanwei Zhou, Xinping Luo, Xue Yang, Minjie Sun

Nano Letters· Volume 24· Issue 38
Publisher page

Abstract

Natural killer (NK) cells offer profound advantages against tumor recurrence due to their unique immunological behavior. NK cell therapies associated with the antibody-dependent cell-mediated cytotoxicity (ADCC) effect have made remarkable progress while being limited by insufficient antibody binding and the exhausted state of NK cells in the postsurgical immunosuppressive microenvironment. Leveraging the adherence of PLT to tumor cells, we developed an exogenously implanted platelet (PLT)-based NK cell-driven system (PLT-IgG-IL15) to improve the identifiability of residual tumors with IgG antibody labeling for NK cells catching and engaging, which consequently restored the ADCC effect and promoted the recovery of their killing function. Furthermore, interleukin-15 (IL-15) participated in the augmentation of NK cell function. Collectively, PLT-IgG-IL15 served as an NK cell tumor cell engager as well as an NK cell charger, achieving a <40% recurrence rate in mouse tumor models.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Immune Cell Function and Interaction · CAR-T cell therapy research · Immune cells in cancer

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

NMPA Key Laboratory for Research and Evaluation of Pharmaceutical Preparations and Excipients, State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China

Funding

Jiangsu Provincial Key Research and Development Program · Natural Science Foundation of Jiangsu Province · National Natural Science Foundation of China

References (43)

Show source-provided references
1. 10.6004/jnccn.2020.001610.6004/jnccn.2020.0016 ↗
2. 10.1002/ctm2.2410.1002/ctm2.24 ↗
3. Bald T. · 2020 · 147 · 61
4. 10.1038/s41573-019-0052-110.1038/s41573-019-0052-1 ↗
5. 10.1038/nri304410.1038/nri3044 ↗
6. 10.1186/s12943-020-01238-x10.1186/s12943-020-01238-x ↗
7. 10.1007/s12026-011-8231-010.1007/s12026-011-8231-0 ↗
8. 10.1016/j.ccell.2017.06.00910.1016/j.ccell.2017.06.009 ↗
9. 10.1182/blood-2009-01-20046910.1182/blood-2009-01-200469 ↗
10. 10.1186/1479-5876-6-2510.1186/1479-5876-6-25 ↗
11. 10.1007/s40263-021-00875-010.1007/s40263-021-00875-0 ↗
12. 10.3389/fimmu.2020.0177110.3389/fimmu.2020.01771 ↗
13. 10.3390/cancers1302031210.3390/cancers13020312 ↗
14. 10.3389/fimmu.2015.0036810.3389/fimmu.2015.00368 ↗
15. 10.1002/adma.20180439510.1002/adma.201804395 ↗
16. 10.1016/j.canlet.2016.02.02410.1016/j.canlet.2016.02.024 ↗
17. 10.1007/BF0272534110.1007/BF02725341 ↗
18. 10.1016/j.semcancer.2022.01.00610.1016/j.semcancer.2022.01.006 ↗
19. 10.1080/08923973.2020.174273310.1080/08923973.2020.1742733 ↗
20. 10.3390/ijms22211137810.3390/ijms222111378 ↗
21. 10.3389/fimmu.2019.0303810.3389/fimmu.2019.03038 ↗
22. 10.1097/SLA.0b013e31826fcbdb10.1097/SLA.0b013e31826fcbdb ↗
23. 10.1182/blood-2014-08-53158210.1182/blood-2014-08-531582 ↗
24. 10.1038/s41551-016-001110.1038/s41551-016-0011 ↗
25. 10.1186/s13045-018-0669-210.1186/s13045-018-0669-2 ↗
26. 10.1038/s41467-022-29388-010.1038/s41467-022-29388-0 ↗
27. 10.1182/blood.202101153210.1182/blood.2021011532 ↗
28. 10.1158/1078-0432.CCR-20-457510.1158/1078-0432.CCR-20-4575 ↗
29. 10.1038/s41591-021-01651-910.1038/s41591-021-01651-9 ↗
30. 10.1038/s41590-019-0511-110.1038/s41590-019-0511-1 ↗
31. 10.1126/scitranslmed.aaf234110.1126/scitranslmed.aaf2341 ↗
32. 10.1038/s41571-020-0426-710.1038/s41571-020-0426-7 ↗
33. 10.3389/fimmu.2020.61466710.3389/fimmu.2020.614667 ↗
34. 10.1016/j.stem.2020.05.00810.1016/j.stem.2020.05.008 ↗
35. 10.1002/ijc.2899710.1002/ijc.28997 ↗
36. 10.1002/JLB.MR0718-269R10.1002/JLB.MR0718-269R ↗
37. 10.1182/blood.V122.21.2283.228310.1182/blood.V122.21.2283.2283 ↗
38. 10.1126/sciadv.aba856410.1126/sciadv.aba8564 ↗
39. 10.1021/accountsmr.2c0004210.1021/accountsmr.2c00042 ↗
40. 10.1016/j.apsb.2021.09.02110.1016/j.apsb.2021.09.021 ↗
41. 10.1146/annurev.immunol.22.012703.10470210.1146/annurev.immunol.22.012703.104702 ↗
42. 10.1038/s41467-019-12771-910.1038/s41467-019-12771-9 ↗
43. 10.1038/s41590-020-0728-z10.1038/s41590-020-0728-z ↗